摘要
应用放射免疫技术同步检测了２１ 例肺癌和２５ 例肺部良性疾病患者的血清 Ｃ Ｙ Ｆ Ｒ Ａ２１－ １ 、 Ｃ Ｅ Ａ、 Ｃ Ａ５０ 及 Ｎ Ｓ Ｅ 的水平， 并分析其灵敏度，特异性，准确率，以探索肺癌辅助诊断的新途径。结果显示：肺癌患者的四种标志物血清水平高于肺部良性疾病患者， 有比较显著的差异（ Ｐ＜０ ．０１） 。肺癌组 Ｃ Ｙ Ｆ Ｒ Ａ２１ － １ 水平９ ．９４ ±１０ ．３６ｎｇ／ｍ Ｌ，非肿瘤组水平２ ．７２ ±２ ．３７ｎｇ／ｍ Ｌ（ Ｐ＜ ０ ．０１） ，肺癌组阳性率６６ ．７ ％ ，非肿瘤组仅为８ ％ 。对比分析四种标志物以不同方式组合的联合检测对肺癌诊断的灵敏度、特异性、准确率， 表明含有 Ｃ Ｙ Ｆ Ｒ Ａ２１ － １ 的三种标志物联合检测对肺癌诊断价值最大， 灵敏度１００ ％ ，特异性８０ ％ ，准确率８０ ．８ ％ 。此四种标志物对肺癌辅助诊断有价值，建议临床工作中采用 Ｃ Ｙ Ｆ Ｒ Ａ２１ － １ 、 Ｃ Ｅ Ａ、 Ｎ Ｓ Ｅ 联合检测。
To explor the new means for diagnosis of lung cancer, serum CYFRA21-1,CEA,CA50 and NSE levels were measured by immunoradiometric assay in 21 patients with lung cancer and 25 patients with benign lung diseases, while the sensitivity, specificity and accuracy of tumor markers were also analysed respectively. The levels of CYFRA21-1,CEA,CA50 and NSE in patiants with lung cancer were significantly higher than those in group with benign lung diseases ( P <0.01). The average CYFRA21-1 levels in patients with lung cancer and patients with benign lung diseases were 9.94±10.36ng/mL and 2.72±2.37ng/mL( P <0.01) respectively.The positive rates in lung cancer group and benign lung diseases group were 66.7% and 8% respectively. The sensitivity, specificity and accuracy of the combined determination contanining CYFRA21-1 were 100%,80% and 80.8% respectively, being higher than other in diagnosis for lung cancer. CYFRA21-1,CEA,CA50 and NSE are significant valuble in adjuvant diagnosis of lung cancer. It is suggested that the determination combined CYFRA21-1,CEA and NSE should be used in clinical medicine.
出处
《标记免疫分析与临床》
CAS
1999年第3期167-169,154,共4页
Labeled Immunoassays and Clinical Medicine
